Article Text

PDF

Controlled trial of hydroxocobalamin and riboflavine in Nigerian ataxic neuropathy
  1. B. O. Osuntokun,
  2. M. J. S. Langman,
  3. J. Wilson1,
  4. A. Aladetoyinbo
  1. Department of Neurology and Psychiatry, University College Hospital, Ibadan, Nigeria
  2. University Department of Medicine, General Hospital, Nottingham
  3. M.R.C. Clinical Genetics Research Unit, Institute of Child Health and Institute of Neurology, London
  4. The Department of Neurology and Psychiatry, University College Hospital, Ibadan, Nigeria

    Abstract

    The results are presented of a double-blind therapeutic trial of hydroxocobalamin and riboflavine in Nigerian patients suffering from a degenerative neuropathy. Although no benefit from either vitamin was demonstrated, this may reflect the inadequacy of the dosages used. The results are discussed in relation to the hypothesis that dietary cyanide and cyanogens are responsible, at least in part, for the occurrence of this disease in a malnourished population.

    Statistics from Altmetric.com

    Footnotes

    • 1 Address for reprints: Dr. J. Wilson, M.R.C. Clinical Genetics Research Unit, National Hospital, Queen Square, London, W.C.1.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.